Navigation Links
Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
Date:1/31/2008

VAP Cholesterol test can help doctors and clinicians identify best

treatment options for patients at risk of heart disease

BIRMINGHAM, Ala., Jan. 31 /PRNewswire/ -- Clinical trial results from a new cholesterol-fighting drug combination point to the need for more detailed cholesterol testing, including direct measurement of LDL and other lipids. That's according to Atherotech, a cardio-diagnostic company that has developed an expanded cholesterol test called the VAP (Vertical Auto Profile) test, which can help doctors and clinicians identify the best treatment options for patients at risk of heart disease.

According to Atherotech Chief Medical Officer James Ehrlich, M.D., media reports about recently released trials have now resulted in widespread concern and confusion about the general value of lipid lowering agents, particularly statins, which play a critically important role in very high risk patients. Ehrlich pointed to a recent BusinessWeek article that raised multiple questions about the role of statins in the prevention of coronary disease, the nation's top killer.

"Atherotech believes that precise physician decisions about lifelong management of hypercholesterolemia can only be accomplished with a detailed profiling of lipoprotein components," said Atherotech Chief Medical Officer James Ehrlich, M.D. "By identifying the patient's true risk and by detailing his/her lipid profile with a VAP test, the physician can now successfully modify risk and improve the lipid levels in a rational manner. Some patients need combination therapy while others are well treated with monotherapy (statins)."

Ehrlich explained that new drugs and therapies are still important tools in helping individuals at risk to reach LDL goals, sometimes without statin therapy. However, he emphasized how we modify lipoprotein patterns may be more important in decreasing the risk of heart attack and stroke than simply lowering LDL cholesterol alone.

Unlike standard cholesterol tests that only measure LDL (bad cholesterol), HDL (good cholesterol), and total cholesterol, Atherotech's VAP test (http://www.thevaptest.com) enables direct, accurate measurement of important lipid subclasses and how they are transported and behave in the blood stream.

People who are already taking cholesterol lowering medication -- or have a family history or an existing condition of diabetes, high blood pressure or heart disease -- are candidates for the comprehensive VAP test, which directly measures fifteen separate components of blood cholesterol, including the identification of risk from lipid subclasses such as Lp(a), low HDL2 and small, dense LDL particles. These detailed measurements then allow the physician or clinician to determine the best therapy for reducing a patient's risk of heart attack and stroke.

The VAP Test is available nationwide.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's VAP Technology. Specifically, VAP is a patented density gradient ultracentrifugation that directly measures the cholesterol content of all lipids, components and subclasses. The VAP test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct low-density lipoprotein (LDL) measurement which is unaffected by triglycerides. Included in Forbes.com's list of "15 ways to Live Longer" and named one of "Five Tests Worth Paying For" by the Wall Street Journal, The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by most payers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
3. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Difficult to Treat Erectile Dysfunction Patients
6. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
10. A Must Read for Breast Cancer Patients
11. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... N.C. (PRWEB) , ... October 09, 2017 , ... At ... announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, ... Stubbs was a member of the winning team for the 2015 Breakthrough Prize in ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
(Date:10/5/2017)... ... ... Understanding the microbiome, the millions of bacteria that live in our guts, is ... the newest exhibit on display at the University City Science Center’s Esther Klein Gallery ... of the gut microbiome. , Gut Love opens October 12, 2017, and runs ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):